Researchers led by the Ministry of Public Health Tucumán, Argentina, recently completed the IVER-Leve clinical trial, organized in response to the challenges with the COVID-19…
Yet another clinical trial result points out the possible benefits of ivermectin in relations to COVID-19 treatments. This time, a study led by researchers from Afyonkarahisar…
A nonsteroidal antiandrogen (NSAA), classified as a selective, high-affinity silent antagonist of the androgen receptor (AR), currently under development by a Chinese biotech company was…
Singapore researchers, led by the National University of Singapore, reported on a large clinical trial conducted last Spring involving over 3,000 migrant workers residing in…
GlaxoSmithKline announced the decision to halt the phase 2 INDUCE-3 and INDUCE-4 trials, which are evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab…
Sage Therapeutics and Biogen reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of patients with essential tremor (ET). The…
Kiniksa announced results from the Phase 2 portion of a phase 2/3 trial of mavrilimumab in non-mechanically ventilated patients (Cohort 1) with severe COVID-19 pneumonia…
Romark announced initial results from a phase 3 trial evaluating NT-300 (nitazoxanide extended-release tablets, 300 mg) versus placebo as a treatment for mild or moderate…
Five months after making an upfront payment of $425 million in cash to acquire OncImmune and its phase 3 COVID-19 therapeutic, CD24Fc, Merck announced it…
A small publicly traded Irish and American biotech called Strongbridge Biopharma plc (Nasdaq: SBBP) recently announced the results from a sub analyses of patients with…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
